BioCentury
ARTICLE | Financial News

resTORbio raises $40M series B

December 1, 2017 9:55 PM UTC

resTORbio Inc. (Boston, Mass.) raised $40 million in an oversubscribed series B round led by OrbiMed Advisors with participation from Fidelity, Rock Springs Capital, Quan Capital and Nest Bio. The aging-related disease company has raised $65 million this year.

resTORbio’s lead candidate, RTB101, is in Phase IIb testing as monotherapy and in combination with Afinitor everolimus to reduce respiratory tract infections in the elderly. Following a safety and efficacy review of 179 subjects, an independent DMC recommended this month that the study proceed into its second stage, which is to enroll 424 patients. resTORbio expects top-line data in 2H18...